GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » Beneish M-Score

Generex Biotechnology (Generex Biotechnology) Beneish M-Score : 0.00 (As of May. 11, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Generex Biotechnology's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Generex Biotechnology was 0.00. The lowest was 0.00. And the median was 0.00.


Generex Biotechnology Beneish M-Score Historical Data

The historical data trend for Generex Biotechnology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generex Biotechnology Beneish M-Score Chart

Generex Biotechnology Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -331.16 -0.83 85.83 3.49 3.37

Generex Biotechnology Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.02 3.37 -4.72 -6.51 -7.15

Competitive Comparison of Generex Biotechnology's Beneish M-Score

For the Biotechnology subindustry, Generex Biotechnology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Generex Biotechnology's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generex Biotechnology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Generex Biotechnology's Beneish M-Score falls into.



Generex Biotechnology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Generex Biotechnology for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0711+0.528 * 1.6582+0.404 * 0.9874+0.892 * 0.3419+0.115 * 0.7309
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 5.1281+4.679 * -0.743919-0.327 * 1.8162
=-7.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Apr21) TTM:Last Year (Apr20) TTM:
Total Receivables was $0.05 Mil.
Revenue was 0.021 + 0 + 0.088 + 0.584 = $0.69 Mil.
Gross Profit was -0.045 + -0.105 + 0.065 + 0.419 = $0.33 Mil.
Total Current Assets was $2.47 Mil.
Total Assets was $45.92 Mil.
Property, Plant and Equipment(Net PPE) was $0.27 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.16 Mil.
Selling, General, & Admin. Expense(SGA) was $29.88 Mil.
Total Current Liabilities was $64.07 Mil.
Long-Term Debt & Capital Lease Obligation was $0.65 Mil.
Net Income was 9.223 + -24.081 + -10.731 + -11.673 = $-37.26 Mil.
Non Operating Income was 15.53 + -15.243 + 4.143 + -5.156 = $-0.73 Mil.
Cash Flow from Operations was 0.577 + -0.98 + -1.336 + -0.634 = $-2.37 Mil.
Total Receivables was $0.14 Mil.
Revenue was 0.499 + 0.857 + 0.722 + -0.051 = $2.03 Mil.
Gross Profit was 0.382 + 0.692 + 0.588 + -0.042 = $1.62 Mil.
Total Current Assets was $2.09 Mil.
Total Assets was $51.90 Mil.
Property, Plant and Equipment(Net PPE) was $0.38 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.56 Mil.
Selling, General, & Admin. Expense(SGA) was $17.04 Mil.
Total Current Liabilities was $39.71 Mil.
Long-Term Debt & Capital Lease Obligation was $0.56 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.052 / 0.693) / (0.142 / 2.027)
=0.075036 / 0.070054
=1.0711

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.62 / 2.027) / (0.334 / 0.693)
=0.799211 / 0.481962
=1.6582

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2.469 + 0.273) / 45.923) / (1 - (2.093 + 0.384) / 51.895)
=0.940291 / 0.952269
=0.9874

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.693 / 2.027
=0.3419

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.557 / (0.557 + 0.384)) / (1.163 / (1.163 + 0.273))
=0.591923 / 0.809889
=0.7309

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(29.875 / 0.693) / (17.04 / 2.027)
=43.109668 / 8.406512
=5.1281

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.654 + 64.074) / 45.923) / ((0.56 + 39.713) / 51.895)
=1.40949 / 0.776048
=1.8162

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-37.262 - -0.726 - -2.373) / 45.923
=-0.743919

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Generex Biotechnology has a M-score of -7.15 suggests that the company is unlikely to be a manipulator.


Generex Biotechnology Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Generex Biotechnology (Generex Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10102 USA Today Way, Miramar, FL, USA, 33025
Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.
Executives
Prioletti Mark Joseph Se director 1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr director 450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines other: Consultant 11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher officer: EVP General Counsel &Secretary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee director 201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr. director 33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao officer: CFO & Treasurer 531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr. director, officer: SVP of Research & Drug Develop 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman director 10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti director 10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro director, officer: SVP & Chief Investment Officer 10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard officer: Chief Operating Officer 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows officer: Chief Financial Officer 33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von director, officer: President of Subsidiary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt director 555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1

Generex Biotechnology (Generex Biotechnology) Headlines

From GuruFocus